Beam Therapeutics to Present Updated Clinical Data from BEACON Phase 1/2 Trial of Risto-cel in Sickle Cell Disease in an Oral Presentation at American Society of Hematology (ASH) Annual Meeting
BEACON Trial Results Selected for Official ASH Press Program
Covered in this story
Call it yourself
No calls on $ASH yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Ashland →Dalsna Finance is currently tracking 5 stories mentioning Ashland, the earliest published 4 Nov 2026.
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.